Immuneering (IMRX) Accounts Payables (2020 - 2026)
Immuneering (IMRX) posted quarterly Accounts Payables of $1.5 million for Q1 2026, up 10.88% year-over-year from $1.3 million in Q1 2025, and down 5.81% quarter-over-quarter from $1.5 million in Q4 2025.
Immuneering (IMRX) Accounts Payables (2020 - 2026) Analysis & Trends
Immuneering's Accounts Payables history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 10.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 10.88% YoY), while the FY2025 annual figure was $1.5 million, down 21.23% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.5 million, down from $1.5 million in the prior quarter.
- The five-year high for Accounts Payables was $3.2 million in Q4 2022, with the low at $1.2 million in Q2 2022.
- The 5-year median for Accounts Payables is $2.0 million (2024), against an average of $2.1 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 126.24% in 2022, then tumbled 42.29% in 2025.
- Immuneering's Accounts Payables stood at $3.2 million in 2022, then plunged by 33.06% to $2.1 million in 2023, then slipped by 7.25% to $2.0 million in 2024, then retreated by 21.23% to $1.5 million in 2025, then decreased by 5.81% to $1.5 million in 2026.
- Business Quant data shows IMRX's Accounts Payables at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Mn |
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Mar 31, 2024 | 2.27 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 2.69 Mn |
| Mar 31, 2023 | 2.72 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 1.80 Mn |